RIMKLB Inhibitors
Chemical inhibitors of RIMKLB function through various molecular mechanisms to impede the protein's activity. LY294002 and Wortmannin are both PI3K inhibitors that obstruct the PI3K/AKT pathway, which is integral to cellular growth and survival signals. By impeding this pathway, these inhibitors can decrease the activity of RIMKLB, which may require PI3K/AKT signaling for its functions. U0126 and PD98059 target the MAPK/ERK pathway by inhibiting MEK1/2, thereby potentially reducing RIMKLB activity, as this kinase pathway could be essential for its function. Similarly, SB203580 and SP600125 disrupt the MAPK pathway but through inhibiting p38 MAPK and JNK, respectively, which could lead to a decrease in RIMKLB activity if it is modulated by stress response or cytokine production signals relayed through these kinases.
Rapamycin, targeting the mTOR pathway, can inhibit downstream processes that might regulate RIMKLB, particularly those associated with cellular metabolism and growth. PP2, an inhibitor of Src family kinases, can attenuate RIMKLB activity by disrupting Src-related signaling pathways. Y-27632, as a ROCK inhibitor, can interrupt the RhoA pathway and consequently RIMKLB activity if it is associated with cytoskeletal dynamics. BIX 02189, a MEK5 inhibitor, could lead to a reduction in RIMKLB activity by interfering with the ERK5 pathway. BIM-1, by inhibiting PKC, can impede signaling pathways that regulate RIMKLB, assuming it is controlled by PKC-mediated signaling. Lastly, Gefitinib, an EGFR inhibitor, can inhibit RIMKLB activity by blocking the EGFR signaling pathways, which may have downstream effects on RIMKLB. Each of these chemicals acts to diminish RIMKLB's activity by obstructing specific signaling pathways that are crucial for the protein's functional expression and its role in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can inhibit RIMKLB by blocking the PI3K/AKT pathway, which is known to be involved in the regulation of various proteins associated with cellular growth and proliferation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, and by inhibiting MEK, it interrupts the MAPK/ERK pathway, which is crucial for the function of a wide array of proteins, including RIMKLB which may rely on this pathway for proper function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can disrupt the p38 MAPK pathway involved in stress response and cytokine production, which could impact the function of RIMKLB as it may play a role in these cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor which can inhibit the ERK pathway; since RIMKLB is a protein kinase, inhibiting upstream kinases within its pathway can reduce its functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor that can lead to the inhibition of AKT, a kinase within the PI3K pathway; inhibiting this pathway may result in decreased RIMKLB activity, as it is likely dependent on signals propagated through PI3K/AKT for its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways; by inhibiting JNK, the function of RIMKLB could be disrupted if the protein's activity is modulated by JNK signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and by inhibiting mTOR, which is a part of the PI3K/AKT pathway, it could inhibit downstream effects that affect RIMKLB function, especially those related to growth and metabolism. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor; as Src kinases can regulate multiple signaling pathways including those that may involve RIMKLB, its inhibition can reduce RIMKLB activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor; ROCK is part of the RhoA pathway, which is involved in cytoskeletal dynamics. Inhibiting ROCK might inhibit RIMKLB if its activity is tied to cytoskeletal rearrangement processes. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $224.00 $386.00 | 5 | |
BIX 02189 is a MEK5 inhibitor; if RIMKLB relies on the ERK5 pathway for its activation or stability, inhibiting MEK5 could reduce the functional activity of RIMKLB. | ||||||